INS018_055 Phase IIa Results: First AI-Designed Drug
Analyze the Phase IIa clinical trial results of INS018_055 (rentosertib), the first AI-designed drug by Insilico Medicine targeting TNIK for IPF treatment.
Back to Articles
Articles tagged with “ins018-055”